World J Mens Health.  2018 May;36(2):103-109. 10.5534/wjmh.170007.

Shifting the Paradigm of Testosterone Replacement Therapy in Prostate Cancer

• Bell MA
• Campbell J
• Joice G
• Sopko NA
• Burnett AL

• KMID: 2419308
• DOI: http://doi.org/10.5534/wjmh.170007

Abstract

Historically, testosterone and prostate cancer have been demonstrated to have a positive association leading providers to forgo testosterone replacement therapy (TRT) in men with concurrent histories of hypogonadism and prostate cancer. This paradigm has been gradually shifting with our evolving understanding of the relationship between testosterone and prostate cancer and the gaining popularity of the saturation model. Newer data suggests improved quality of life for men with hypogonadism after TRT leading to a more tempered view of the effects of this treatment and its risk in prostate cancer. As more reports emerge of TRT in men who have either undergone definitive treatment for prostate cancer or are on active surveillance, some providers see a role for TRT in these patients despite non-consensus in clinical guidelines. It is critical that we examine evidence currently available, while we await more rigorous data to emerge.

Keyword

Androgens; Hypogonadism; Prostate-specific antigen; Prostatic neoplasm; Testosterone

MeSH Terms

Androgens
Humans
Hypogonadism
Male
Prostate*
Prostate-Specific Antigen
Prostatic Neoplasms*
Quality of Life
Testosterone*
Androgens
Prostate-Specific Antigen
Testosterone

Reference

1. Traish AM, Miner MM, Morgentaler A, Zitzmann M. Testosterone deficiency. Am J Med. 2011; 124:578–587.

2. McBride JA, Carson CC 3rd, Coward RM. Testosterone deficiency in the aging male. Ther Adv Urol. 2016; 8:47–60.

3. Paduch DA, Brannigan RE, Fuchs EF, Kim ED, Marmar JL, Sandlow JI. The laboratory diagnosis of testosterone deficiency. Urology. 2014; 83:980–988.

4. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010; 95:2536–2559.

5. Elliott J, Kelly SE, Millar AC, Peterson J, Chen L, Johnston A, et al. Testosterone therapy in hypogonadal men: a systematic review and network meta-analysis. BMJ Open. 2017; 7:e015284.

6. Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 2004; 89:2085–2098.

7. Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016; 374:611–624.

8. National Cancer Institute. Cancer of the prostate - cancer stat facts [Internet]. Bethesda (MD): National Cancer Institute;c2017. cited 2017 Nov 8. Available from: https://seer.cancer.gov/statfacts/html/prost.html.

9. Luthy KE, Williams C, Freeborn DS, Cook A. Comparison of testosterone replacement therapy medications in the treatment of hypogonadism. J Nurse Pract. 2017; 13:241–249.

10. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol. 2008; 159:507–514.

11. Bassil N, Alkaade S, Morley JE. The benefits and risks of testosterone replacement therapy: a review. Ther Clin Risk Manag. 2009; 5:427–448.

12. Huggins C, Hodges CV. Studies on prostatic cancer I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941; 1:293–297.

13. Gooren LJ, Behre HM. Diagnosing and treating testosterone deficiency in different parts of the world: changes between 2006 and 2010. Aging Male. 2012; 15:22–27.

14. Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol. 2009; 55:310–320.

15. American Urological Association. AUA position statement on testosterone therapy [Internet]. Linthicum (MD): American Urological Association;c2015. cited 2017 Nov 8. Available from: http://www.auanet.org/guidelines/testosterone-therapy.

16. Morgentaler A. Guilt by association: a historical perspective on Huggins, testosterone therapy, and prostate cancer. J Sex Med. 2008; 5:1834–1840.

17. Tindall DJ, Rittmaster RS. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer. J Urol. 2008; 179:1235–1242.

18. Dehm SM, Tindall DJ. Molecular regulation of androgen action in prostate cancer. J Cell Biochem. 2006; 99:333–344.

19. Kurita T, Wang YZ, Donjacour AA, Zhao C, Lydon JP, O'Malley BW, et al. Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system. Cell Death Differ. 2001; 8:192–200.

20. Joseph IB, Nelson JB, Denmeade SR, Isaacs JT. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res. 1997; 3:2507–2511.

21. Morgentaler A. Testosterone replacement therapy and prostate cancer. Urol Clin North Am. 2007; 34:555–563. vii

22. Wright AS, Douglas RC, Thomas LN, Lazier CB, Rittmaster RS. Androgen-induced regrowth in the castrated rat ventral prostate: role of 5alpha-reductase. Endocrinology. 1999; 140:4509–4515.

23. Traish AM, Muller RE, Wotiz HH. A new procedure for the quantitation of nuclear and cytoplasmic androgen receptors. J Biol Chem. 1981; 256:12028–12033.

24. Traish AM, Williams DF, Hoffman ND, Wotiz HH. Validation of the exchange assay for the measurement of androgen receptors in human and dog prostates. Prog Clin Biol Res. 1988; 262:145–160.

25. Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism. JAMA. 2006; 296:2351–2361.

26. Endogenous Hormones, Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008; 100:170–183.

27. Debruyne FMJ, Behre HM, Roehrborn CG, Maggi M, Wu FCW, Schröder FH, et al. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men. BJU Int. 2017; 119:216–224.

28. McLaren D, Siemens DR, Izard J, Black A, Morales A. Clinical practice experience with testosterone treatment in men with testosterone deficiency syndrome. BJU Int. 2008; 102:1142–1146.

29. Cooper CS, MacIndoe JH, Perry PJ, Yates WR, Williams RD. The effect of exogenous testosterone on total and free prostate specific antigen levels in healthy young men. J Urol. 1996; 156:438–441. discussion 441-2.

30. Gerstenbluth RE, Maniam PN, Corty EW, Seftel AD. Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement. J Androl. 2002; 23:922–926.

31. Guay AT, Perez JB, Fitaihi WA, Vereb M. Testosterone treatment in hypogonadal men: prostate-specific antigen level and risk of prostate cancer. Endocr Pract. 2000; 6:132–138.

32. Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol. 2004; 172:920–922.

33. Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol. 2005; 173:533–536.

34. Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer. 2007; 109:536–541.

35. Pastuszak AW, Pearlman AM, Godoy G, Miles BJ, Lipshultz LI, Khera M. Testosterone replacement therapy in the setting of prostate cancer treated with radiation. Int J Impot Res. 2013; 25:24–28.

36. Pastuszak AW, Pearlman AM, Lai WS, Godoy G, Sathyamoorthy K, Liu JS, et al. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol. 2013; 190:639–644.

37. Pastuszak AW, Khanna A, Badhiwala N, Morgentaler A, Hult M, Conners WP, et al. Testosterone therapy after radiation therapy for low, intermediate and high risk prostate cancer. J Urol. 2015; 194:1271–1276.

38. Kaplan AL, Trinh Q, Sun M, Carter SC, Nguyen PL, Shih YT, et al. Testosterone replacement therapy following the diagnosis of prostate cancer: outcomes and utilization trends. J Sex Med. 2014; 11:1063–1070.

39. Kaplan AL, Lenis AT, Shah A, Rajfer J, Hu JC. Testosterone replacement therapy in men with prostate cancer: a time-varying analysis. J Sex Med. 2015; 12:374–380.

40. Ory J, Flannigan R, Lundeen C, Huang JG, Pommerville P, Goldenberg SL. Testosterone therapy in patients with treated and untreated prostate cancer: impact on oncologic outcomes. J Urol. 2016; 196:1082–1089.

41. Morgentaler A, Rhoden EL. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urology. 2006; 68:1263–1267.

42. Morgentaler A, Lipshultz LI, Bennett R, Sweeney M, Avila D Jr, Khera M. Testosterone therapy in men with untreated prostate cancer. J Urol. 2011; 185:1256–1260.

43. Morales A. Effect of testosterone administration to men with prostate cancer is unpredictable: a word of caution and suggestions for a registry. BJU Int. 2011; 107:1369–1373.

44. San Francisco IF, Rojas PA, DeWolf WC, Morgentaler A. Low free testosterone levels predict disease reclassification in men with prostate cancer undergoing active surveillance. BJU Int. 2014; 114:229–235.

45. Kacker R, Hult M, San Francisco IF, Conners WP, Rojas PA, Dewolf WC, et al. Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results. Asian J Androl. 2016; 18:16–20.

46. Dohle GR, Colpi GM, Hargreave TB, Papp GK, Jungwirth A, Weidner W. EAU Working Group on Male Infertility. EAU guidelines on male infertility. Eur Urol. 2005; 48:703–711.

47. Khera M, Adaikan G, Buvat J, Carrier S, El-Meliegy A, Hatzimouratidis K, et al. Diagnosis and treatment of testosterone deficiency: recommendations from the fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med. 2016; 13:1787–1804.

48. Millar AC, Elterman DS, Goldenberg L, Van Asseldonk B, Curtis A, Jarvi K. A survey of Canadian urologists' opinions and prescribing patterns of testosterone replacement therapy in men on active surveillance for low-risk prostate cancer. Can Urol Assoc J. 2016; 10:181–184.